<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20020715101621Z</creation_date><modification_date>D:20060321214301+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-01-178_h_a_dec_1.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communitiesbrussels, 11/07/2002c(2002) 2733
 not for publication</p></section><section><header>commission decisionof [...........................]
 amending decision c(2001)818 on the marketing authorization for
 the medicinal product for human use
 &quot;targretin - bexarotene&quot;
 (text with eea relevance)</header><p>only the english text is authentic.</p></section><section><header>commission decisionof 11/07/2002
 amending decision c(2001)818 on the marketing authorization for
 the medicinal product for human use
 &quot;targretin - bexarotene&quot;
 (text with eea relevance)</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down
 community procedures for the authorization and supervision of medicinal products for
 human and veterinary use and establishing a european agency for the evaluation of
 medicinal products
 1, as amended by commission regulation (ec) no 649/982,having regard to commission regulation (ec) no 542/95 of 10 march 1995 concerning
 the examination of variations to the terms of a marketing authorisation falling within the
 scope of council regulation (eec) no 2309/93
 3, as amended by commissionregulation (ec) no 1069/98
 4, and in particular article 5(2) thereof,having regard to the opinion of the european agency for the evaluation of medicinal
 products,
 whereas:
 (1)</p><p>the medicinal product &quot;targretin - bexarotene&quot; entered in the community
 register of medicinal products under no eu/1/01/178/001 authorised by
 commission decision c(2001)818 of 29 march 2001, as amended, complies with
 the requirements set out in regulation (eec) no 2309/93.
 (2)</p><p>ligand pharmaceuticals uk ltd submitted an application on 28 may 2002
 pursuant to article 4(1) set out in regulation (ec) no 542/95.
 (3)</p><p>the european agency for the evaluation of medicinal products delivered a
 favourable opinion formulated on 11 june 2002 by the committee for proprietary
 medicinal products,
 (4)</p><p>decision c(2001)818 should therefore be amended accordingly.</p><p> 
 1 oj no l 214, 24. 8. 1993, p. 1.2 oj l 88, 24.3.1998, p. 7.3 oj no l 55, 11.3.1995, p. 154 oj l 153, 27.5.1998, p. 11(5) in accordance with article 5(2) of regulation (ec) no 542/95, this decision shall
 take effect retroactively on the 31st day following receipt by the european
 agency for the evaluation of medicinal products of the application relating to it.
 has adopted this decision:
 article 1decision c(2001)818 is amended as follows:1. annex i is replaced by annex i to this decision;
 2. annex iii (a and b) is replaced by annex ii to this decision.
 article 2this decision shall apply from 27 june 2002.article 3this decision is addressed to ligand pharmaceuticals uk ltd, innovis house, 108 highstreet, crawley, west sussex rh10 1bb, united kingdom.
 done at brussels, 11/07/2002
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>